Project description DEENESFRITPL Selection of viable embryos for IVF procedure The low rates of pregnancy during in vitro fertilisation (IVF) procedures are due to a lack of technology to evaluate the viability of embryos for transfer. The current practice of multiple embryo transfer is a costly procedure associated with many risks, averaging a success rate of only 1 in 4. Carmel Diagnostics in Israel has developed and validated an innovative device to use oxidative stress biomarkers for the selection of viable embryos in a rapid, non-invasive procedure. The goal of the EU-funded Fertissimo project is to conduct a series of retrospective and prospective clinical validation studies to qualify the novel biomarker for accurate prediction of embryo viability. This will lay the foundation for dependable IVF pregnancies in the future. Show the project objective Hide the project objective Objective Low rates of pregnancy in IVF procedure is due to being unable to identify viable embryos for transfer. As a result, multiple embryo transfer (MET) is practiced to increase the chances of pregnancy. This is a costly procedure with riskier outcomes, which on average only equates to a 1 out of 4 rate of pregnancy success. In order to minimise the cost and risk outcomes with MET, there are increasing trends have been adopted to accommodate single embryo transfer (SET). SET however, requires more efficient embryo selection tools than current legacy morphology methods.Fertissimo utilises a novel biomarker of oxidative stress (OS) qualities that will enable the physician’s selection of viable embryos in a rapid, non-invasive, and accurate manner. Fertissimo will provide a quantitative assessment of an embryo’s reproductive potential based on the oxidative profile of its incubated culture media. It will increase IVF pregnancy outcomes by an unprecedented 25% and beyond.The Phase 2 project’s ultimate aim is to lay the foundation for dependable IVF pregnancies of the future. Fertissimo will set the gold standard for IVF procedure in all relevant IVF facilities, located in hospitals, medical centres, centres of IVF excellence, and clinics. Carmel Diagnostics will conduct a series of clinical validation studies, both retrospective and prospective, in order to qualify the novel OS biomarker to effectively predict embryo viability Carmel Diagnostics (established in 2009) joins forces with Aran R&D, a leading engineering and product development company, forming a solid basis with all necessary knowledge capabilities, infrastructure and finances to support the innovation project. This would allow Carmel, and Aran, to develop, test, certify, and create the production line required for Fertissimo’s mass production. The industrially produced Fertissimo can then be qualified in a conclusive clinical trial with Global IVF Leader IVI Valencia to the benefit of soon-to-be mothers Fields of science medical and health sciencesclinical medicinegynaecologyreproductive medicinesocial scienceseconomics and businesseconomicsmonetary and financesengineering and technologymaterials engineeringmedical and health sciencesclinical medicineobstetricsmedical and health sciencesclinical medicineembryology Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Call for proposal H2020-SMEInst-2016-2017 See other projects for this call Sub call H2020-SMEINST-2-2016-2017 Funding Scheme SME-2 - SME instrument phase 2 Coordinator CARMEL DIAGNOSTICS LTD Net EU contribution € 1 446 486,00 Address 9 BARLEV HAIM STREET 3608267 QIRYAT TIVON Israel See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 1 486 486,00 Participants (1) Sort alphabetically Sort by Net EU contribution Expand all Collapse all ARAN RESEARCH DEVELOPMENT & PROTOTYPES LTD Israel Net EU contribution € 1 265 487,50 Address 43 HAESHEL ST 38900 CAESAEA See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 1 265 487,50
